Expert Ratings
Easily search Stocks, Mutual Funds, Articles and Videos
Track the companies of Group.
| Sales Growth | Profit Growth | Expense Growth | Stock Price CAGR |
|---|---|---|---|
Presentation & Earning Calls |
Annual Reports |
Credit Rating |
|---|---|---|
|
|
|
|
Fermenta Biotech an established enterprise with a rich seven-decade history, operates across diverse sectors, including pharmaceuticals, animal feed, nutrition, integrated biotech, environmental solutions and real estate. A key focal point of the company’s expertise lies in the comprehensive manufacturing of Vitamin D3. The Company maintains a sustainable supply chain, providing a notable advantage in the contemporary global market.
The company’s array of Vitamin D3 variants is finely balanced to meet the requirements of both human and animal nutrition, rendering them applicable across a broad spectrum of uses. In addition to Vitamin D3 products, the company engages in the production of APIs for muscle relaxants and anti-flatulent applications. The Company also pioneers the development of innovative enzymes crucial for manufacturing active pharmaceutical ingredients, alongside offering environmental solutions for wastewater treatment and management.
The strategic possession of legacy properties in Thane and Worli, Mumbai, serves as a lucrative source of income for the company. This supplementary revenue stream complements the core business activities, reinforcing the Company’s financial position. Through a development agreement with Mextech Property Developers LLP, the company is poised to construct residential-cum-commercial buildings on its free-hold Thane land and would acquire affordable luxury residential apartments from Mextech on an area sharing basis.
Furthermore, the company has undertaken sale transactions for its IT/ITES building, Thane One. As of the report date, the company has successfully divested a significant portion of the IT/ITES building to third parties. The proceeds from these transactions were judiciously utilized to retire outstanding loans associated with the IT/ITES building.
Business area of the company
The company is engaged in the business of manufacturing and marketing of chemicals, bulk drugs, enzymes, pharmaceutical formulations and environmental solution products and renting and selling of properties. The Company caters to both domestic and international markets. The company also has strategic investments in subsidiaries primarily dealing in manufacturing and marketing bulk drugs.
Business Segments
Awards
Milestones/ History
Comment